BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36900378)

  • 1. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
    Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
    Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE
    Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer.
    Lee S; Cavaliere A; Gallezot JD; Keler T; Michelhaugh SK; Belitzky E; Liu M; Mulnix T; Maher SE; Bothwell ALM; Li F; Phadke M; Mittal S; Marquez-Nostra B
    Mol Cancer Ther; 2022 Mar; 21(3):440-447. PubMed ID: 35027482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of [
    Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the theranostic potential of
    Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
    EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Massicano AVF; Song PN; Mansur A; White SL; Sorace AG; Lapi SE
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
    Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
    Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
    Maric G; Rose AA; Annis MG; Siegel PM
    Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
    Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
    Diebolder P; Mpoy C; Scott J; Huynh TT; Fields R; Spitzer D; Bandara N; Rogers BE
    J Nucl Med; 2021 Jan; 62(1):137-143. PubMed ID: 32513906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
    Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
    Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
    Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.